Lucas Rodriguez, CerSci [Photo: Skyler Fike]
CerSci shareholders could net another $887 million in milestones and tiered royalties. The clinical-stage startup, which launched in 2015, is developing a new generation of non-opioid meds to treat acute and chronic pain.